Trial · NCT07896044
Stoppa Approach Vs Anterior & Posterior Fixation in Management of BC Fracture Acetabulum
NCT07896044, Phase 2, Active not recruiting, Ain Shams University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Stoppa Approach Vs Anterior & Posterior Fixation in Management of BC Fracture Acetabulum. Trials, record NCT07896044. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896044
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Stoppa Approach Vs Anterior & Posterior Fixation in Management of BC Fracture Acetabulum
- NCT number
- NCT07896044
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, actual
- Lead sponsor
- Ain Shams University
- Conditions
- Evaluation of Isolated Stoppa Approach in BC Fracture Acetabulum
- Interventions
- Sequential anterior and posterior approaches for double column acetabular fractures, Isolated Modified Stoppa approach for management of double column acetabular fractures
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of excellent, very good, good, average, or poor functional outcomes using the modified Merle d'Aubigné scoring system | 1 year postoperative | Clinical assessment was done via the Modified Merle d'Aubigné scoring system that was calculated at each follow-up visit (out of 18) and presented the mean value; the score evaluates three factors: pain, mobility \& ability to walk. The score maximum is 18 (excellent) and minimum is 6 (poor) |
| Primary | Rate of Anatomical, Congruent, or Incongruent Radiological Outcomes According to the Matta and Tornetta Radiological Principles | 1 year postoperative | Radiological outcomes will be evaluated according to the Matta and Tornetta Radiological Principles using anteroposterior pelvic radiographs. Assessment will be based on restoration of the five anatomical lines: the iliopectineal line, ilioischial line, acetabular dome, anterior wall, and posterior wall. Each participant will be classified into one of three ordered categories: Anatomical, representing the best radiological outcome; congruent, representing an intermediate radiological outcome with preserved joint congruence; or incongruent, representing the worst radiological outcome with loss of joint congruence. The number and percentage of participants in each category will be reported for each treatment group. This is a categorical classification rather than a numerical scale; therefore, numerical minimum and maximum values do not apply. |
| Primary | Rate of implant failure | Up to 12 months after surgery. | The incidence of implant failure will be compared between the isolated modified Stoppa approach with posterior column screw fixation group and the sequential anterior and posterior column fixation group. Implant failure will be defined as plate or screw breakage, bending, loosening, pull-out, migration, or loss of implant position identified on follow-up radiographs. Revision surgery performed because of mechanical failure of the fixation construct will also be recorded as an implant failure event. The rate will be calculated as the number of patients who develop implant failure divided by the total number of evaluable patients in each group, multiplied by 100. |
| Primary | Rate of recurrent fracture diastasis or secondary loss of reduction | From immediately after surgery through 12 months after surgery. | Recurrent fracture diastasis will be defined as an increase of more than 2 mm in the postoperative displacement or separation of either the anterior or posterior acetabular column compared with the immediate postoperative radiographs. Assessment will be performed using standardized anteroposterior pelvic and Judet radiographs, with computed tomography obtained when plain radiographs are inconclusive. Revision surgery due to recurrent displacement or loss of reduction will also be recorded as an event. The rate will be calculated as the number of affected patients divided by the total number of evaluable patients in each group, multiplied by 100. |
| Secondary | Mean intraoperative blood loss | up to 4 days postoperative | The mean blood loss was calculated and compared between the two study groups, it was measured intraoperative and postoperative from suction drains |
| Secondary | Mean operative time | It was calculated intraoperatively | The mean operation time was calculated in minutes and compared between the two study groups |
| Secondary | Rate of unplanned reoperation | Up to 12 months after the index operation. | The incidence of unplanned reoperation related to the index acetabular fracture or its surgical fixation will be compared between the two treatment groups. Reoperation will include revision fixation, implant removal due to complications, surgical treatment of infection, conversion to total hip arthroplasty, or any other unplanned surgical procedure related to failure of the initial treatment. Routinely planned procedures unrelated to a complication will not be considered reoperations. The reoperation rate will be calculated as the number of patients requiring at least one unplanned additional operation divided by the total number of evaluable patients in each group, multiplied by 100. The indication and type of each additional operation will also be recorded. |
| Secondary | Rate of postoperative surgical-site infection | p to 90 days after surgery. For implant-related or late infections, events will continue to be recorded for up to 12 months. | The incidence of postoperative surgical-site infection will be compared between the two treatment groups. Infection will be classified as superficial incisional infection, involving only the skin or subcutaneous tissue, or deep incisional infection, involving the deep soft tissues, fascia, muscle, or fixation implants. Diagnosis will be based on clinical findings such as purulent wound discharge, wound dehiscence, erythema, swelling, local tenderness, fever, positive microbiological culture, or the need for antibiotic or surgical treatment. The infection rate will be calculated as the number of patients diagnosed with a surgical-site infection divided by the total number of evaluable patients in each group, multiplied by 100. |
| Secondary | Quality of intraoperative acetabular fracture reduction | Intraoperatively, immediately after definitive fixation and before wound closure. | he quality of fracture reduction will be assessed intraoperatively after definitive fixation using fluoroscopic anteroposterior and Judet views. The maximum residual displacement or fracture gap involving the anterior column, posterior column, and articular surface will be measured in millimetres. Reduction will be classified according to the maximum residual displacement as anatomical (0-1 mm), imperfect (2-3 mm), or poor (greater than 3 mm). The measured displacement and distribution of reduction categories will be compared between the two treatment groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40889944 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896044
GET https://conductscience.org/api/trials/v1/NCT07896044/registered